AstraZeneca Investors Reject Bristol-Myers Squibb Merger Proposal

AstraZeneca investors expressed significant opposition to a proposed $400 billion merger with Bristol-Myers Squibb, signaling they see little strategic value in the deal. The negative investor sentiment suggests concerns about the transaction's logic and potential benefits to shareholders. Bloomberg Intelligence's Sam Fazeli commented on the investor pushback against the tie-up.